# Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

> **NCT04348292** · PHASE1 · TERMINATED · sponsor: **Emory University** · enrollment: 3 (actual)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage I Lung Cancer AJCC v8
- Stage IA1 Lung Cancer AJCC v8
- Stage IA2 Lung Cancer AJCC v8
- Stage IA3 Lung Cancer AJCC v8
- Stage IB Lung Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Stage IIA Lung Cancer AJCC v8
- Stage IIB Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT04348292
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-22
- **Primary completion:** 2022-11-04
- **Final completion:** 2022-11-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Accrual goal not met.
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348292, "Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04348292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*